anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RimabotulinumtoxinB is an acetylcholine release inhibitor. RimabotulinumtoxinB is a 700 kDA botulinum toxin type B complex produced from fermentation of the bacterium Clostridium botulinum type B (Bean strain) and exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps. 

MYOBLOC (rimabotulinumtoxinB) injection is a sterile, preservative-free, clear and colorless to light-yellow solution in a single-dose vial for intramuscular or intraglandular use. Each vial contains 2,500 Units/0.5 mL; 5,000 units/mL; or 10,000 Units/2 mL of rimabotulinumtoxinB at a concentration of 5,000 Units/mL at approximately pH 5.6.

Each 2,500 Units/0.5 mL vial of MYOBLOC contains 2,500 Units rimabotulinumtoxinB, 0.235 mg albumin human, 2.9 mg sodium chloride and 1.35 mg sodium succinate.

Each 5,000 Units/mL vial of MYOBLOC contains 5,000 Units rimabotulinumtoxinB, 0.47 mg albumin human, 5.8 mg sodium chloride and 2.7 mg sodium succinate.

Each 10,000 Units/2 mL vial of MYOBLOC contains 10,000 Units rimabotulinumtoxinB, 0.94 mg albumin human, 11.6 mg sodium chloride and 5.4 mg sodium succinate.

One unit of MYOBLOC corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. The method for performing the assay is specific to Solstice Neurosciences' manufacture of MYOBLOC. Due to differences in specific details such as the vehicle, dilution scheme and laboratory protocols for various mouse LD50 assays, Units of biological activity of MYOBLOC cannot be compared to or converted into Units of any other botulinum toxin or any toxin assessed with any other specific assay method. Therefore, differences in species sensitivities to different botulinum neurotoxin serotypes preclude extrapolation of animal dose-activity relationships to human dose estimates. The specific activity of MYOBLOC ranges between 70 to 130 Units/ng.
The invention is concerned with a kind of inactivated vaccine and preparation method to anti-monkey SV40 virus, belonging to animal vaccine. It carries multiplication, inactivation and purification to prepare inactivated vaccine of anti-monkey SV40 virus. This vaccine is SV40 virus and adjuvant inactivated with beta-Propiolactone and the cubage of them is 2:1 to 3:2. Mix the said component with buffer solution and get Tween-20 with 0.03 to 0.05 mg/ml and glycine with 2.0 to 4.0mg/ml, and the virus content is 104.6 to 5.2TCID50/ml. Purificate the SV40 virus liquid with 0 percent CPE to collect virus, inactivate and stop SV40 virus with beta-Propiolactone and use adjuvant absorb inactivated SV40virus. The specific antibody caused of small rat can identify SV40virus with security. The tested monkey can produce neutralizing antibody with singularity, and the neutralizing antibody with singularity can stop the infection of SV40virus to cell culturing matter during the test. This inactivated vaccine maybe has natural anti-infection function.
Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
PURPOSE:To obtain a pencil type cosmetic without exuding a fat or oil component in a core material, by forming a semicircular groove in each interior of a pair of halved split sticks, coating the whole length of the split sticks with an oil-resistant synthetic resin, and nipping the core material constituting the cosmetic or perfume between the split sticks. CONSTITUTION:A semicircular groove (13a) is formed in the interior of each halved split stick (incense cedar wood) (11a), and the whole length and the boundary line between the flat part and the semicircular groove (13a) is coated with an oil-resistant synthetic resin (14a). A core material 16 constituting a cosmetic or perfume is then nipped between the halved split sticks and joined under pressure to give a pencil type cosmetic, e.g. eyebrow pencil, eyeshadow pencil, eyeliner pencil or lip pencil, and a pencil type solid perfume. The resultant pencil type cosmetic and perfume have a coating film of the oil-resistant synthetic resin, e.g. an acrylic resin, between the core material 16 and the sticks (11a), and the fat or oil component will not exude to the stick part. Thus, there are no disadvantages, e.g. deterioration in quality or beautiful sight of the cosmetic or perfume.
BACKGROUND: As a leading cause of mortality and long-term disability, acute ischemic stroke can produce far-reaching pathophysiological consequences. Accumulating evidence has demonstrated abnormalities in the lower motor system following stroke, while the existence of Transsynaptic degeneration of contralateral spinal cord ventral horn (VH) neurons is still debated.
METHODS: Using a rat model of acute ischemic stroke, we analyzed spinal cord VH neuron counts contralaterally and ipsilaterally after stroke with immunofluorescence staining. Furthermore, we estimated the overall lower motor unit abnormalities after stroke by simultaneously measuring the modified neurological severity score (mNSS), compound muscle action potential (CMAP) amplitude, repetitive nerve stimulation (RNS), spinal cord VH neuron counts, and the corresponding muscle fiber morphology. The activation status of microglia and extracellular signal-regulated kinase 1/2 (ERK 1/2) in the spinal cord VH was also assessed.
RESULTS: At 7 days after stroke, the contralateral CMAP amplitudes declined to a nadir indicating lower motor function damage, and significant muscle disuse atrophy was observed on the same side; meanwhile, the VH neurons remained intact. At 14 days after focal stroke, lower motor function recovered with alleviated muscle disuse atrophy, while transsynaptic degeneration occurred on the contralateral side with elevated activation of ERK 1/2, along with the occurrence of neurogenic muscle atrophy. No apparent decrement of CMAP amplitude was observed with RNS during the whole experimental process.
CONCLUSIONS: This study offered an overview of changes in the lower motor system in experimental ischemic rats. We demonstrated that transsynaptic degeneration of contralateral VH neurons occurred when lower motor function significantly recovered, which indicated the minor role of transsynaptic degeneration in lower motor dysfunction during the acute and subacute phases of focal ischemic stroke.
A formulation having wound healing properties, such as an acceleration of wound healing, comprises amorphous microparticles or nanoparticles of a salt of polyphosphate and a divalent cation, preferably calcium or magnesium. The salt may be formed by adding a solution of a salt of a divalent cation to an aqueous sodium polyphosphate solution, which has been adjusted to pH 10.0 through the addition of an alkali, such as sodium hydroxide. The formed particles may be stirred overnight and collected by filtration. Preferably the formulation also comprises an alginate or collagen. A wound dressing may comprise the nanoparticles or microparticles embedded in an electrospun meshwork consisting of polylactide (or its copolymers), polycaprolactone (or its copolymers), or another biocompatible polymer. The formulation may alternatively be provided as a powder or gel. Preferably, the formulation is used in the treatment of wounds in patients showing delayed wound healing, such as in the elderly, or diabetic patients.
The presently disclosed device includes a plurality of vials each bearing a unique identifier and in discrete locations in the device. An alignment assembly aligns one of the discrete locations with an access point for dispensing one of the vials. Computer executable instructions select a vial to be dispensed and store inventory information of the vials. The inventory information associates the unique identifiers with a status for each the plurality of vials indicating whether a vial is: loaded, dispensed, returned, or remaining undispensed in the device. The computer executable instructions also deactivate dispensing of the vials from the device based on at least one signal received from at least one environmental sensor configured to detect one of: location, temperature, humidity, vibration, shock, blood alcohol content (BAC), and light intrusion. A deactivation assembly deactivates dispensing of the vials based on the instructions.
Factor VIII and IX clotting factor concentrates manufactured from pooled plasma have been identified as potent sources of virus infection in persons with hemophilia (PWHs) in the 1970s and 1980s. To investigate the range and diversity of viruses over this period, we analysed 24 clotting factor concentrates for several blood-borne viruses. Nucleic acid was extracted from 14 commercially produced clotting factors and 10 from nonremunerated donors, preserved in lyophilized form (expiry dates: 1974-1992). Clotting factors were tested by commercial and in-house quantitative PCRs for blood-borne viruses hepatitis A, B, C and E viruses (HAV, HBV, HCV, HEV), HIV- types 1/2, parvoviruses B19V and PARV4, and human pegiviruses types 1 and 2 (HPgV-1,-2). HCV and HPgV-1 were the most frequently detected viruses (both 14/24 tested) primarily in commercial clotting factors, with frequently extremely high viral loads in the late 1970s-1985 and a diverse range of HCV genotypes. Detection frequencies sharply declined following introduction of virus inactivation. HIV-1, HBV, and HAV were less frequently detected (3/24, 1/24, and 1/24 respectively); none were positive for HEV. Contrastingly, B19V and PARV4 were detected throughout the study period, even after introduction of dry heat treatment, consistent with ongoing documented transmission to PWHs into the early 1990s. While hemophilia treatment is now largely based on recombinant factor VIII/IX in the UK and elsewhere, the comprehensive screen of historical plasma-derived clotting factors reveals extensive exposure of PWHs to blood-borne viruses throughout 1970s-early 1990s, and the epidemiological and manufacturing parameters that influenced clotting factor contamination.
Systems, methods, and computer program product embodiments are disclosed for filtering noise from an input signal. An embodiment accesses the input signal having a first harmonic frequency and having the noise. The embodiment determines a quiet period in the input signal. The embodiment stores samples of the noise of the input signal in a buffer during the quiet period. The embodiment subtracts the samples from a single cycle of the noise in the buffer from the input signal to create a filtered signal. The embodiment then repeats the determining, storing, and subtracting to refine the filtered signal.
Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
Reading disorders are diagnosed and remediated in a subject by respectively measuring and improving contrast sensitivity for motion discrimination of the subject. A background is displayed on a monitor with a contrast and a spatial frequency. A test window is superimposed over the background and includes a test pattern with a contrast and a spatial frequency. The contrasts and the spatial frequencies are within respective ranges which stimulate the visual cortical movement system of the subject. The test pattern is then moved within the test window. The subject provides a signal indicative of the direction the subject believes the test pattern moved. In response to this signal, the contrast of the test pattern, the spatial frequency of the background, or the spatial frequency of the test pattern is modified, either by increasing or decreasing its respective value. This process is then repeated a number of times, cycling through predetermined combinations of test patterns and backgrounds. Contrast sensitivity may be measured to determine whether a child is dyslexic. Repeated stimulation by the methods and apparatus of the invention improves contrast sensitivity, thereby remediating dyslexia and improving reading ability.
This phase of the study will have two arms developed through random allocation: one arm for intravenous autologous bone marrow derived stem cell/mononuclear cells(BMMC arm); and second control arm. Patients with acute ischaemic stroke between 7-30 days after onset with moderae severity in sable condition will be entered into the study after informed consent. Both arms will receive standard treatment but BMMC arm will,in addition,have bone marrow aspiration and receive autologous 30-500 million bone marrow mononuclear cells intravenously on the day of randomisation and all patients will be followed at DaY 7 ± days, Day 90(-7 days to +14 days), Day 180(-7 days to +28 days)and Day 365 (-7 days to + 28 days). A number of safety and efficacy variables will be measured. This phase 2 study will aim to determine dose response gradient of stem cell therapy and to explore if results have a favourable risk to benefit ratio to justify a phase 3 study. This will be the first human trial to determine and compare favourable and unfavourable effects of bone marrow mononuclear cells(mainly CD34) in acute ischamic stroke and also the first multi-centric study with potential to achieve a reasonable sample size in a relatively short time.
Cancer, defined by the continuous, uncontrollable proliferation of cells in the human body, is a disease with a rapidly increasing incidence and mortality rate. Scientists are looking for novel ways to cure and prevent this sneaky disease because of the toxicity of contemporary chemotherapy and the cancer cells' resilience to anticancer drugs. Determining the effect of herbal medicines, which do not have as harmful side effects as synthetic drugs, on cancer cell lines is an essential preliminary study in the production of effective drugs against cancer. In this study, the phenolic acid profile, antioxidant capacity, and cytotoxicity of the medicinal plant Mespilus germanica (MG) leaf extract were determined, and its effects on the expression of some apoptotic, necrotic, and autophagic pathway genes of MCF7 (Human breast cancer line) and A549 (Human lung cancer line) and healthy HDF (Human Dermal Fibroblasts) cells were investigated for the first time. The LCMS device detected many important phenolic compounds previously reported to act against cancer cells in Mespilus germanica leaf extract. DPPH and total phenolic content showed high antioxidant capacity. The cytotoxicity of MG was determined by the MTT method. The levels of mRNA transcription for Atg5, Atg3, Rıpk1, Bcl2, Bax, Apaf1, Caspase-8, Caspase-7, Caspase-3, and Caspase-9, as well as the expression patterns of the DNA damage markers P53 and Parp-1 genes, were assessed. MG leaf extract did not cause significant toxicity against healthy HDF cells. However, it had a cytotoxic effect on A549 and MCF7 cancer cell lines, increasing the transcription levels of essential genes involved in cell death mechanisms. This research is the first to analyze the phenolic components and antioxidant capabilities of leaf extracts from Mespilus germanica. Additionally, it investigates the impact of these extracts on crucial genes involved in cell death pathways of A549 lung cancer, MCF7 breast cancer, and non-cancerous HDF (Human Dermal Fibroblasts) cells.
BACKGROUND: The effect of His bundle pacing (HBP) on the incidence of new-onset atrial fibrillation (AF) after pacemaker implantation (PMI) for atrioventricular conduction disturbance (AVCD) remains unknown. We compared the incidence of new-onset atrial high-rate episode (AHRE) in conventional right ventricular (RV) septum pacing (RVSP) and His bundle pacing (HBP) after PMI for AVCD.
METHODS: One hundred and four consecutive patients who underwent dual chamber PMI for AVCD in our hospital were screened. Thirty-five patients with mitral or aortic valve disease, history of open-heart surgery, prior AF, subclinical AF, cumulative ventricular pacing percentage < 90%, and RV lead revision were excluded, and 69 patients were effectively enrolled in this study. The primary endpoint was new-onset AHRE within the follow-up period. New-onset AHRE was defined as an atrial high-rate episode that occurred 3 months after PMI and lasted for > 6 min at an atrial heart rate > 190 bpm. RV leads were placed in the His bundle region and RV septum region in 22 and 47 patients, respectively. The mean follow-up period was 539 ± 218 days. The follow-up period was 2 years after PMI or until the new-onset AHRE occurred.
RESULTS: The incidence of new-onset AHRE was lower in the HBP group than in the RVSP group (11% vs. 43%, p = 0.01). Multivariate analysis in the Cox regression hazard model showed that HBP had a significantly lower risk of new-onset AHRE compared with RVSP (HR = 0.21; 95% confidence interval 0.04-0.78, p = 0.02).
CONCLUSION: The incidence of new-onset AHRE was significantly less in HBP compared to RVSP during the 2-year follow-up period after pacemaker implantation in AVCD patients with RV pacing dependence.
Historical data have shown that microfilaricidal drugs, such as diethylcarbamazine citrate (DEC-C), might cause cutaneous and/or systemic reactions of varying severity (the Mazzotti reaction) and ophthalmological reactions in patients with onchocerciasis. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Patients treated with STROMECTOL for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the drug itself. (See ADVERSE REACTIONS, Onchocerciasis.) 

The treatment of severe Mazzotti reactions has not been subjected to controlled clinical trials. Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. Antihistamines and/or aspirin have been used for most mild to moderate cases.
Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
1318554 Intrauterine devices MICHAEL REESE HOSPITAL & MEDICAL CENTER 12 June 1970 [16 June 1969] 28616/70 Heading A5R An intrauterine device comprises at least one capsule containing a progestin contained within a partially permeable wall. In the embodiment shown in Fig. 1, the device comprises three silicone elastomer tubes 11, 12, 13 containing progestin. These tubes are joined by polyethylene corner pieces 14, 15, 16 so that the whole aquires a generally triangular shape. In other embodiments (not shown) the device may comprise rings, spirals, bows or double S loops. The triangular device may be elastically distended so that it is easily inserted into the uterus using the forked applicator (21) and a string (22) (Fig. 2). Oncee the device is in place the capsules slowly release the progestin at a rate dependent upon the directions of the capsule walls. The recommended progestin is d1-11#-ethyl-17a-ethinyl-17#-hydroxygon-4-ene -3-one although others are exemplified.
The present disclosure provides fusion proteins with novel signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component that is capable of binding to a TGF[beta] polypeptide, a transmembrane component, and an intracellular component comprising a cytoplasmic domain from an IL-2R[beta] or IL-2R[gamma] protein. Certain embodiments include a TGF[beta]R intracellular overhang or overhang sequence extending from a TGF[beta]R transmembrane domain, N-terminal to the IL-2R cytoplasmic domain. In response to TGF[beta], the fusion proteins can initiate an IL-2 signal in a host cell, promoting, for example, proliferation of the host cells. Recombinant host cells expressing the fusion proteins, and an optional antigen-binding protein such as a TCR or a CAR, are provided. Also provided are polynucleotides encoding the fusion proteins, and vectors that comprise the polynucleotides. Also provided are compositions and methods comprising the same.
At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
Depression is a prevalent mental disorder, but the side effects of antidepressants also make depressed patients resistant. Effective and safe antidepressants should be developed from traditional herbs, with the aim of reducing the side effects of antidepressants and improving the efficacy of drugs. In this study, the new macamide compound-4 (NMC-4) was synthesized for the first time, addressing the problem of difficult extraction, isolation, and low content of natural macamide. NMC-4 was characterized using mass spectrometry, nuclear magnetic resonance, and infrared spectroscopy. The protective effect of NMC-4 against cell injury was demonstrated to be stronger than that of natural macamide (N-benzylhexadecanamide, XA) using a PC12 cell injury model. The study explored the effects of NMC-4 on chronic unpredictable mild stress (CUMS)-induced depressive symptoms. NMC-4 significantly improved depressive-like behaviors. NMC-4 ameliorated CUMS-induced depressive-like behaviors by mitigating neuroinflammation and modulating the NF-κB/Nrf2 and BDNF/PI3K/Akt pathways.
The comparator is Bio-Oss®, deproteinized bovine bone granules (granule size 0.25- 1mm). Bio-Oss® is osteoconductive, which means it acts as a scaffold only for new bone to grow.